Lucia de Stephanis1, Anna Bonon1, Katia Varani2, Giovanni Lanza3, Roberta Gafà3, Paolo Pinton4, Monika Pema5, Stefan Somlo6, Alessandra Boletta5, Gianluca Aguiari7. 1. Section of Biochemistry, Molecular Biology and Medical Genetics, Department of Biomedical and Surgical Specialty Sciences, University of Ferrara, via Fossato di Mortara, 74, 44121, Ferrara, Italy. 2. Section of Pharmacology, Department of Medical Sciences, University of Ferrara, via Fossato di Mortara, 17-19, 44121, Ferrara, Italy. 3. Section of Pathological Anatomy and Molecular Diagnostic, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, via Aldo Moro 8, 44124, Ferrara, Italy. 4. Section of Pathology, Oncology and Experimental Biology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, via Fossato di Mortara 64/b, 44121, Ferrara, Italy. 5. Dibit 1 San Raffaele, via Olgettina 60, 20132, Milan, Italy. 6. Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06520, USA. 7. Section of Biochemistry, Molecular Biology and Medical Genetics, Department of Biomedical and Surgical Specialty Sciences, University of Ferrara, via Fossato di Mortara, 74, 44121, Ferrara, Italy. dsn@unife.it.
Abstract
BACKGROUND: ADPKD is a renal pathology caused by mutations of PKD1 and PKD2 genes, which encode for polycystin-1 (PC1) and polycystin-2 (PC2), respectively. PC1 plays an important role regulating several signal transducers, including cAMP and mTOR, which are involved in abnormal cell proliferation of ADPKD cells leading to the development and expansion of kidney cysts that are a typical hallmark of this disease. Therefore, the inhibition of both pathways could potentiate the reduction of cell proliferation enhancing benefits for ADPKD patients. METHODS: The inhibition of cAMP- and mTOR-related signalling was performed by Cl-IB-MECA, an agonist of A3 receptors, and rapamycin, respectively. Protein kinase activity was evaluated by immunoblot and cell growth was analyzed by direct cell counting. RESULTS: The activation of A3AR by the specific agonist Cl-IB-MECA causes a marked reduction of CREB, mTOR, and ERK phosphorylation in kidney tissues of Pkd1 flox/-: Ksp-Cre polycystic mice and reduces cell growth in ADPKD cell lines, but not affects the kidney weight. The combined sequential treatment with rapamycin and Cl-IB-MECA in ADPKD cells potentiates the reduction of cell proliferation compared with the individual compound by the inhibition of CREB, mTOR, and ERK kinase activity. Conversely, the simultaneous application of these drugs counteracts their effect on cell growth, because the inhibition of ERK kinase activity is lost. CONCLUSION: The double treatment with rapamycin and Cl-IB-MECA may have synergistic effects on the inhibition of cell proliferation in ADPKD cells suggesting that combined therapies could improve renal function in ADPKD patients.
BACKGROUND: ADPKD is a renal pathology caused by mutations of PKD1 and PKD2 genes, which encode for polycystin-1 (PC1) and polycystin-2 (PC2), respectively. PC1 plays an important role regulating several signal transducers, including cAMP and mTOR, which are involved in abnormal cell proliferation of ADPKD cells leading to the development and expansion of kidney cysts that are a typical hallmark of this disease. Therefore, the inhibition of both pathways could potentiate the reduction of cell proliferation enhancing benefits for ADPKD patients. METHODS: The inhibition of cAMP- and mTOR-related signalling was performed by Cl-IB-MECA, an agonist of A3 receptors, and rapamycin, respectively. Protein kinase activity was evaluated by immunoblot and cell growth was analyzed by direct cell counting. RESULTS: The activation of A3AR by the specific agonist Cl-IB-MECA causes a marked reduction of CREB, mTOR, and ERK phosphorylation in kidney tissues of Pkd1 flox/-: Ksp-Cre polycysticmice and reduces cell growth in ADPKD cell lines, but not affects the kidney weight. The combined sequential treatment with rapamycin and Cl-IB-MECA in ADPKD cells potentiates the reduction of cell proliferation compared with the individual compound by the inhibition of CREB, mTOR, and ERK kinase activity. Conversely, the simultaneous application of these drugs counteracts their effect on cell growth, because the inhibition of ERK kinase activity is lost. CONCLUSION: The double treatment with rapamycin and Cl-IB-MECA may have synergistic effects on the inhibition of cell proliferation in ADPKD cells suggesting that combined therapies could improve renal function in ADPKD patients.
Authors: Wouter N Leonhard; Annemieke van der Wal; Zlata Novalic; Steven J Kunnen; Ron T Gansevoort; Martijn H Breuning; Emile de Heer; Dorien J M Peters Journal: Am J Physiol Renal Physiol Date: 2011-02-23
Authors: Andreas L Serra; Diane Poster; Andreas D Kistler; Fabienne Krauer; Shagun Raina; James Young; Katharina M Rentsch; Katharina S Spanaus; Oliver Senn; Paulus Kristanto; Hans Scheffel; Dominik Weishaupt; Rudolf P Wüthrich Journal: N Engl J Med Date: 2010-06-26 Impact factor: 91.245
Authors: Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Jared J Grantham; Eiji Higashihara; Ronald D Perrone; Holly B Krasa; John Ouyang; Frank S Czerwiec Journal: N Engl J Med Date: 2012-11-03 Impact factor: 91.245
Authors: Sara J Holditch; Carolyn N Brown; Daniel J Atwood; Deepak Pokhrel; Sara E Brown; Andrew M Lombardi; Khoa N Nguyen; Ryan C Hill; Miguel Lanaspa; Katharina Hopp; Mary C M Weiser-Evans; Charles L Edelstein Journal: Hum Mol Genet Date: 2019-12-15 Impact factor: 6.150
Authors: Michelle H T Ta; Kristina G Schwensen; Sheryl Foster; Mayuresh Korgaonkar; Justyna E Ozimek-Kulik; Jacqueline K Phillips; Anthony Peduto; Gopala K Rangan Journal: PLoS One Date: 2016-10-10 Impact factor: 3.240